Arrhythmias & electrophysiology
No Effect of Continued Antiarrhythmic Drug Treatment on Top of Optimized Pulmonary Vein Isolation in Patients With Persistent Atrial Fibrillation: Results From the POWDER-AF2 Trial
Authors' conclusion
In patients with PersAF, there is no benefit in continuing previously ineffective ADT beyond the blanking period after catheter ablation.
Study context
- Population
- Patients with persistent AF (≥7 days and <12 months) despite class 1C or 3 antiarrhythmic drug therapy (ADT), undergoing standardized pulmonary vein isolation (PVI)-only ablation (CLOSE protocol)
- Participants
- 200 patients
- Comparison
- Continued vs discontinued ADT after PVI
- ADT ONn = 102
- ADT OFFn = 98reference
- Primary endpoint
- Any documented atrial tachyarrhythmia lasting >30 seconds
- Follow-up
- Beyond 3 months
Methodological detailsmulticentre, 1:1 randomisation, Clinical visits and 1-to-7-day Holter at 3, 6 and 12 months
- Multicentre
- 1:1 randomisation
- Clinical visits and 1-to-7-day Holter at 3, 6 and 12 months
Primary result
As reported in the abstract
Recurrence of atrial tachyarrhythmia
Secondary outcomes
Repeat ablations and unscheduled arrhythmia-related visits
- No differences between groups
Quality of life
- Marked improvement in both groups
Original publication
No Effect of Continued Antiarrhythmic Drug Treatment on Top of Optimized Pulmonary Vein Isolation in Patients With Persistent Atrial Fibrillation: Results From the POWDER-AF2 Trial. Circ Arrhythm Electrophysiol. Published 3 November 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →